News about HER2DX

Researchers identify a link between the immune system and survival after breast cancer

Researchers from Hospital Clínic-IDIBAPS have led a study that has found a correlation between anti-tumour immunological activity and longevity in br1

Clínic Barcelona

Research October 31 2024

Updated findings on dual HER2 inhibition in HER2+ breast cancer

Researchers from the Clínic-IDIBAPS, along with researchers from the Dana Farber Cancer Institute (DFCI) in Boston, have published a review on dual H1

Clínic Barcelona

Research March 1 2024

A European project led by IDIBAPS will test a diagnostic genomic test for breast cancer to improve patients' quality of life

The DEFINITIVE project, led by IDIBAPS, will be conducted across 44 hospitals in a total of 7 European and associated countries to demonstrate that u1

Clínic Barcelona

Institutional November 11 2022

HER2DX® recognized by TIME as one of the best inventions of 2022

HER2DX® was highlighted in Times \'Medical Care\' category, which publicizes inventions that are successfully implemented in medical practice.

Clínic Barcelona

Research January 25 2022

Developed the first genomic test for personalized HER2+ breast cancer treatments

The new test, called HER2DX, analyzes RNA on 27 genes to predict survival outcomes and the likelihood that patients will respond to treatment.

News about HER2DX

Researchers identify a link between the immune system and survival after breast cancer

Updated findings on dual HER2 inhibition in HER2+ breast cancer

A European project led by IDIBAPS will test a diagnostic genomic test for breast cancer to improve patients' quality of life

HER2DX® recognized by TIME as one of the best inventions of 2022

Developed the first genomic test for personalized HER2+ breast cancer treatments

Subscribe to the Newsletter of Clínic